**Core Concept**
Strontium-89 and Rhenium-186 are radioactive isotopes used in the palliative treatment of metastatic bone pain, which is a common complication of cancer. These isotopes are selectively taken up by bone tissue, allowing for localized radiation therapy to relieve pain.

**Why the Correct Answer is Right**
Strontium-89 is a beta emitter that selectively localizes in bone tissue, providing targeted radiation therapy to relieve bone pain. Rhenium-186 is also a beta emitter that is used for similar purposes. The use of these isotopes in palliative care is based on their ability to deliver radiation directly to the site of bone metastases, reducing the need for systemic chemotherapy and its associated side effects.

**Why Each Wrong Option is Incorrect**
**Option A:** I–131 is primarily used for the treatment of thyroid cancer, particularly in the management of hyperthyroidism and thyroid metastases.

**Option B:** Gold–198 is a radioactive isotope that was historically used in the treatment of certain cancers, but it is not commonly used for the relief of metastatic bone pain.

**Option C:** Phosphorus-32 (P–32) is a radioactive isotope that is used in the treatment of certain blood disorders, including polycythemia vera and chronic myeloid leukemia.

**Option D:** Rhenium-186 is indeed a correct answer, so we will skip it.

**Clinical Pearl / High-Yield Fact**
When considering the treatment of metastatic bone pain, it's essential to remember that the primary goal is to provide palliative care and improve the patient's quality of life. Radioactive isotopes like Strontium-89 and Rhenium-186 can be effective in achieving this goal by delivering targeted radiation therapy to the affected bone tissue.

**Correct Answer:** a) Strontium–89